Cat.No：GM-87845AB
Product：Anti-CEACAM5-SN38(Dar6)[Labetuzumab govitecan]
Cat.No：GM-87845AB
Product：Anti-CEACAM5-SN38(Dar6)[Labetuzumab govitecan]
GM-87845AB-100 100μg
GM-87845AB-1mg 1mg
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 5.0-6.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target CEACAM5
Clone Labetuzumab govitecan
Alternative Names CD66e, CEA
Source/lsotype Monoclonal Human IgG1, kappa
Application Positive control of Cytotoxicity Assay
Description Labetuzumab govitecan is an antibody-drug conjugate (ADC) targeting CEACAM5. Its mechanism of action involves the antibody (labetuzumab) specifically binding to CEACAM5, which is highly expressed on the surface of cancer cells, and being internalized into the cell via endocytosis. In the intracellular environment of tumor cells, the linker attached to the antibody is enzymatically cleaved to release SN-38 (a topoisomerase I inhibitor), which blocks DNA replication and transcription, ultimately leading to cancer cell death. Additionally, the released SN-38 can diffuse to neighboring tumor cells, generating a bystander effect that further enhances the overall antitumor efficacy. This targeted drug delivery mechanism not only significantly improves therapeutic outcomes but also effectively reduces toxicity to normal tissues.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Cat.No：GM-87845AB
Product：Anti-CEACAM5-SN38(Dar6)[Labetuzumab govitecan]
GM-87845AB-100 100μg
GM-87845AB-1mg 1mg
Expression System CHO
Purity >95% as determined by SDS-PAGE
Aggregation < 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR) 5.0-6.0
Endotoxin <1 EU/mg
Sterility 0.22 μm Filtered
Target CEACAM5
Clone Labetuzumab govitecan
Alternative Names CD66e, CEA
Source/lsotype Monoclonal Human IgG1, kappa
Application Positive control of Cytotoxicity Assay
Description Labetuzumab govitecan is an antibody-drug conjugate (ADC) targeting CEACAM5. Its mechanism of action involves the antibody (labetuzumab) specifically binding to CEACAM5, which is highly expressed on the surface of cancer cells, and being internalized into the cell via endocytosis. In the intracellular environment of tumor cells, the linker attached to the antibody is enzymatically cleaved to release SN-38 (a topoisomerase I inhibitor), which blocks DNA replication and transcription, ultimately leading to cancer cell death. Additionally, the released SN-38 can diffuse to neighboring tumor cells, generating a bystander effect that further enhances the overall antitumor efficacy. This targeted drug delivery mechanism not only significantly improves therapeutic outcomes but also effectively reduces toxicity to normal tissues.
Formulation Phosphate-buffered solution, pH 7.2-7.4.
Storage temp. Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
